PEMBROLIZUMAB

Brand name:

• Keytruda®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Oesophageal carcinoma or HER-2-negative gastroesophageal adenocarcinoma

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

Change to listing (–)

Comment:

--

Submission sponsor:

Merck Sharp & Dohme (Australia) Pty Ltd

Other PBAC consideration:

--

Submission received for:

November 2021 PBAC meeting

Opportunity for consumer comment:

Open 28/07/2021 and close 22/09/2021 (see PBS Website)

PBAC meeting:

Held on 03/11/2021

PBAC outcome published:

Not Recommended (see PBAC Outcomes)

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---